360 Results

People

  1. Herr
    Herr
  2. Bajorin
    Bajorin
  3. Rosenberg
    Rosenberg
  4. Dalbagni
    Dalbagni
  5. Al-Ahmadie
    Al-Ahmadie
  6. Reuter
    Reuter
  7. Bochner
    Bochner
  8. Iyer
    Iyer
  9. Scher
    Scher
  10. Cordon-Cardo
    Cordon-Cardo

Groups

  1. Department of Medicine (163)
  2. Solid Tumor Oncology Division (157)
  3. Genitourinary Oncology Service (145)
  4. Surgery (131)
  5. Urology (124)
  6. Department of Pathology and Laboratory Medicine (90)
  7. Epidemiology and Biostatistics (41)
  8. Survivorship Research (40)
  9. GSK Faculty (30)
  10. Population Sciences Research Program (25)
  1. "transitional cell carcinoma"
Formats
  1. Journal Article (314)
  2. Review (29)
  3. Editorial (4)
  4. Guidelines (4)
  5. Meeting Abstract (3)
  6. Correspondence (2)
  7. Research Letter (2)
  8. Book Section (1)
  9. Conference Paper (1)
Groups
  1. Department of Medicine (163)
  2. Solid Tumor Oncology Division (157)
  3. Genitourinary Oncology Service (145)
  4. Surgery (131)
  5. Urology (124)
  6. Department of Pathology and Laboratory Medicine (90)

More Groups

People
  1. Dean Bajorin (68)
  2. Harry Herr (67)
  3. Jonathan Rosenberg (60)
  4. Guido Dalbagni (47)
  5. Hikmat Al-Ahmadie (43)
  6. Victor Reuter (42)

More People

Years
  1. 2025 (17)
  2. 2024 (24)
  3. 2023 (24)
  4. 2022 (17)
  5. 2021 (9)
  6. 2020 (21)

More Years

Publications
  1. Journal of Urology (39)
  2. Journal of Clinical Oncology (22)
  3. European Urology (18)
  4. Cancer (17)
  5. BJU International (12)
  6. Urology (11)

More Publications

Publishers
  1. Elsevier Science, Inc. (80)
  2. Elsevier Inc. (39)
  3. Wiley Blackwell (37)
  4. American Society of Clinical Oncology (25)
  5. Nature Publishing Group (19)
  6. American Association for Cancer Research (16)

More Publishers

Results (360)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: Enfortumab vedotin plus pembrolizumab
    Review

    Hoimes, C. J.; Flaig, T. W.; Milowsky, M. I.; Friedlander, T. W.; Bilen, M. A.; Gupta, S.; Srinivas, S.; Merchan, J. R.; McKay, R. R.; Petrylak, D. P.; more...
    Future Oncology (2024)

    Fulltext@MSK | Save
  • Biparametric versus multiparametric magnetic resonance imaging for assessing muscle invasion in bladder urothelial carcinoma with variant histology using the Vesical Imaging Reporting and Data System
    Journal Article

    Arita, Y.; Kwee, T. C.; Woo, S.; Shigeta, K.; Ishii, R.; Okawara, N.; Edo, H.; Waseda, Y.; Vargas, H. A.
    European Urology Focus (2023)

    Fulltext@MSK | Save
  • Consultation on UTUC II Stockholm 2022: Diagnostic and prognostic methods—What’s around the corner?
    Review

    Grahn, A.; Coleman, J. A.; Eriksson, Y.; Gabrielsson, S.; Madsen, J. S.; Tham, E.; Thomas, K.; Turney, B.; Uhlén, P.; Vollmer, T.; more...
    World Journal of Urology (2023)

    Fulltext@MSK | Save
  • EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma
    Journal Article

    Rosenberg, J. E.; Powles, T.; Sonpavde, G. P.; Loriot, Y.; Duran, I.; Lee, J. L.; Matsubara, N.; Vulsteke, C.; Castellano, D.; Mamtani, R.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Feasibility and tissue concordance of genomic sequencing of urinary cytology in upper tract urothelial carcinoma
    Journal Article

    Katims, A. B.; Gaffney, C.; Firouzi, S.; Yip, W.; Aulitzky, A.; Pietzak, E. J.; Donat, S. M.; Bochner, B. H.; Donahue, T. F.; Herr, H. W.; more...
    Urologic Oncology: Seminars and Original Investigations (2023)

    Fulltext@MSK | Save
  • Clinical and genomic landscape of FGFR3-altered urothelial carcinoma and treatment outcomes with erdafitinib: A real-world experience
    Journal Article

    Guercio, B. J.; Sarfaty, M.; Teo, M. Y.; Ratna, N.; Duzgol, C.; Funt, S. A.; Lee, C. H.; Aggen, D. H.; Regazzi, A. M.; Chen, Z.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • The promise and limitations of neoadjuvant immune-checkpoint blockade in resectable non–small cell lung cancer
    Editorial

    Cooper, A. J.; Yu, H. A.
    Cancer Discovery (2023)

    Fulltext@MSK | Save
  • Integration of peripheral blood- and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinoma
    Journal Article

    Vanguri, R. S.; Smithy, J. W.; Li, Y.; Zhuang, M.; Maher, C. A.; Aleynick, N.; Peng, X.; Al-Ahmadie, H.; Funt, S. A.; Rosenberg, J. E.; more...
    Journal of Pathology (2023)

    Fulltext@MSK | Save
  • Checkpoint inhibitors in urothelial carcinoma—Future directions and biomarker selection
    Review

    Meeks, J. J.; Black, P. C.; Galsky, M.; Grivas, P.; Hahn, N. M.; Hussain, S. A.; Milowsky, M. I.; Steinberg, G. D.; Svatek, R. S.; Rosenberg, J. E.
    European Urology (2023)

    Fulltext@MSK | Save
  • Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer
    Journal Article

    O'Donnell, P. H.; Milowsky, M. I.; Petrylak, D. P.; Hoimes, C. J.; Flaig, T. W.; Mar, N.; Moon, H. H.; Friedlander, T. W.; McKay, R. R.; Bilen, M. A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save